Clinical TrialJul 13, 2026, 09:02 AM
Cadrenal CAD-1005 Phase 2 Data Shows >25% Thrombotic Event Reduction
AI Summary
Cadrenal Therapeutics announced late-breaking Phase 2 clinical data for its lead candidate, CAD-1005, presented at the ISTH 2026 Congress. The data highlighted CAD-1005 as the first randomized, blinded, placebo-controlled trial for Heparin-Induced Thrombocytopenia (HIT), showing an absolute reduction of over 25% in thrombotic events. This supports the clinical advancement of the Phase 3-ready program, which targets a life-threatening condition with an estimated $2 billion in peak annual revenue and no approved root-cause therapies.
Key Highlights
- CAD-1005 Phase 2 data presented at ISTH 2026 Congress in Paris.
- Trial is the first randomized, blinded, placebo-controlled study for Heparin-Induced Thrombocytopenia (HIT).
- CAD-1005 demonstrated an absolute reduction of over 25% in thrombotic events.
- The program is considered Phase 3-ready, targeting an estimated $2 billion in peak annual revenue.
- CAD-1005 holds Orphan Drug and Fast Track designations from the FDA and EMA.
Price Impact
More from CVKD